Showing 35,961 - 35,980 results of 108,461 for search '(( 5 ((026 decrease) OR (a decrease)) ) OR ( a ((point decrease) OR (nn decrease)) ))', query time: 1.65s Refine Results
  1. 35961

    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells by Madhu Biyani (12427332)

    Published 2022
    “…One of the identified aptamers, Apt-7, showed a 5.8-fold higher binding affinity with CYP24 than the similar competitor CYP27B1. …”
  2. 35962

    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells by Madhu Biyani (12427332)

    Published 2022
    “…One of the identified aptamers, Apt-7, showed a 5.8-fold higher binding affinity with CYP24 than the similar competitor CYP27B1. …”
  3. 35963

    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells by Madhu Biyani (12427332)

    Published 2022
    “…One of the identified aptamers, Apt-7, showed a 5.8-fold higher binding affinity with CYP24 than the similar competitor CYP27B1. …”
  4. 35964

    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells by Madhu Biyani (12427332)

    Published 2022
    “…One of the identified aptamers, Apt-7, showed a 5.8-fold higher binding affinity with CYP24 than the similar competitor CYP27B1. …”
  5. 35965

    Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus by Danwei Yu (9206768)

    Published 2021
    “…In the inhibition of a panel of HIV-1 mutants resistant to HIV-1 fusion inhibitors, EK1V1 and IPB02-based inhibitors exhibited significantly decreased or increased activities, suggesting the heptad repeat-1 region (HR1) of HIV-1 gp41 being their target. …”
  6. 35966

    FLIM FRET efficiency of: (A) αA-crystallin (B) WT αB-crystallin, their deamidated and domain mutants. by Ekta Tiwary (836674)

    Published 2015
    “…<p>FRET efficiency was calculated from the decrease in life-lime (presented in Fig 8) in 5 to 6 cells. …”
  7. 35967
  8. 35968
  9. 35969
  10. 35970

    Image_2_Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2.jpeg by Mariette Barbier (526468)

    Published 2022
    “…<p>Emergence of variants of concern (VOC) during the COVID-19 pandemic has contributed to the decreased efficacy of therapeutic monoclonal antibody treatments for severe cases of SARS-CoV-2 infection. …”
  11. 35971

    Image_1_Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2.jpeg by Mariette Barbier (526468)

    Published 2022
    “…<p>Emergence of variants of concern (VOC) during the COVID-19 pandemic has contributed to the decreased efficacy of therapeutic monoclonal antibody treatments for severe cases of SARS-CoV-2 infection. …”
  12. 35972

    Image_3_Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2.jpeg by Mariette Barbier (526468)

    Published 2022
    “…<p>Emergence of variants of concern (VOC) during the COVID-19 pandemic has contributed to the decreased efficacy of therapeutic monoclonal antibody treatments for severe cases of SARS-CoV-2 infection. …”
  13. 35973

    Image_1_Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2.jpeg by Mariette Barbier (526468)

    Published 2022
    “…<p>Emergence of variants of concern (VOC) during the COVID-19 pandemic has contributed to the decreased efficacy of therapeutic monoclonal antibody treatments for severe cases of SARS-CoV-2 infection. …”
  14. 35974

    Image_3_Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2.jpeg by Mariette Barbier (526468)

    Published 2022
    “…<p>Emergence of variants of concern (VOC) during the COVID-19 pandemic has contributed to the decreased efficacy of therapeutic monoclonal antibody treatments for severe cases of SARS-CoV-2 infection. …”
  15. 35975

    Image_2_Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2.jpeg by Mariette Barbier (526468)

    Published 2022
    “…<p>Emergence of variants of concern (VOC) during the COVID-19 pandemic has contributed to the decreased efficacy of therapeutic monoclonal antibody treatments for severe cases of SARS-CoV-2 infection. …”
  16. 35976

    Image_5_Ginsenoside Rd Ameliorates Auditory Cortex Injury Associated With Military Aviation Noise-Induced Hearing Loss by Activating SIRT1/PGC-1α Signaling Pathway.JPEG by Xue-min Chen (9145472)

    Published 2020
    “…Forty-eight guinea pigs were randomly divided into four equal groups (normal control group, noise group, experimental group that received GSRd dissolved in glycerin through an intraperitoneal injection at a dose of 30 mg/kg body weight from 5 days before noise exposure until the end of the noise exposure period, and experimental control group). …”
  17. 35977
  18. 35978

    <b>Tirzepatide Associated with Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Cli... by Ellen M. Apperloo (20405468)

    Published 2025
    “…To examine the generalizability of these findings, we assessed change from baseline in UACR for tirzepatide (5, 10, and 15 mg) compared with active and placebo treatment in a broad population from the SURPASS-1-5 trials.…”
  19. 35979

    A Distorted Cubic Tetranuclear Copper(II) Phosphonate Cage with a Double-Four-Ring-Type Core by Vadapalli Chandrasekhar (815391)

    Published 2008
    “…The reaction of Cu<sub>2</sub>(O<sub>2</sub>CMe)<sub>4</sub>·2H<sub>2</sub>O with <i>tert</i>-butylphosphonic acid and 3,5-di-<i>tert</i>-butylpyrazole in the presence of triethylamine leads to a high-yield synthesis of the tetranuclear compound [Cu<sub>2</sub>(3,5-<i>t</i>-Bu<sub>2</sub>PzH)<sub>2</sub>(<i>t</i>-BuPO<sub>3</sub>)<sub>2</sub>]<sub>2</sub> (<b>1</b>). …”
  20. 35980